Results 191 to 200 of about 6,254,499 (310)
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto +13 more
wiley +1 more source
Navigating the complex currents of risk environments among people who use drugs: A commentary. [PDF]
Bilgrei OR, Hanoa K.
europepmc +1 more source
Malignant Mesothelioma Clinical Trial Combines Immunotherapy Drugs [PDF]
Monica Sheila Chatwal, Tawee Tanvetyanon
openalex +1 more source
Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells
Despite the strong activity of selective RET tyrosine kinase inhibitors (TKIs), resistance of RET fusion‐positive (RET+) lung cancer and thyroid cancer frequently occurs and is mainly driven by RET‐independent bypass mechanisms. Son et al. show that SRC TKIs significantly inhibit PAK and AKT survival signaling and enhance the efficacy of RET TKIs in ...
Juhyeon Son +13 more
wiley +1 more source
Surrogate Endpoints in Pivotal Clinical Trials for Drug Approval in Japan Compared to the United States. [PDF]
Yamamoto Y, Kosaka H, Nojiri H, Maeda H.
europepmc +1 more source
Antifibrotic drugs for idiopathic pulmonary fibrosis
Vijay Hadda, Randeep Guleria
openalex +1 more source
Generation of two normal and tumour (cancerous) paired human cell lines using an established tissue culture technique and their characterisation is described. Cell lines were characterised at cellular, protein, chromosome and gene expression levels and for HPV status.
Simon Broad +12 more
wiley +1 more source

